Combo approved in EU across major HCV genotypes

The European Commission has granted Maviret (glecaprevir/pibrentasvir) marketing authorization for chronic hepatitis C virus (HCV) in all major genotypes.

This treatment, discovered during the ongoing collaboration between US drugmaker AbbVie (NYSE: ABBV) and biotech firm Enanta Pharmaceuticals (Nasdaq:ENTA), is a new eight-week, pan-genotypic treatment for adult HCV without cirrhosis and who are new to treatment.

Alice Butler, medical director of AbbVie UK, said: “The treatment combines two distinct anti-viral agents and has high efficacy against most HCV genotypes, including those commonly associated with resistance to treatment.”